Arrowhead price target raised to $100 from $85 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Arrowhead (ARWR) to $100 from $85 and keeps a Buy rating on the shares after Arrowhead hosted an obesity webinar and sell-side breakfast on January 6 and January 13, respectively, during which the company presented “compelling” interim Phase 1/2a data and “incremental strategic color that establish obesity as a credible growth pillar.” Together with the emerging central nervous system platform, the firm adds that it views the recent meetings as “a step-change in Arrowhead’s long-term value proposition.”